JP2021523918A5 - - Google Patents

Info

Publication number
JP2021523918A5
JP2021523918A5 JP2020564243A JP2020564243A JP2021523918A5 JP 2021523918 A5 JP2021523918 A5 JP 2021523918A5 JP 2020564243 A JP2020564243 A JP 2020564243A JP 2020564243 A JP2020564243 A JP 2020564243A JP 2021523918 A5 JP2021523918 A5 JP 2021523918A5
Authority
JP
Japan
Prior art keywords
crystalline form
pyrazolo
pyridine
methyl
pharmaceutical composition
Prior art date
Application number
JP2020564243A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019220390A5 (https=
JP7407740B2 (ja
JP2021523918A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054066 external-priority patent/WO2019220390A1/en
Publication of JP2021523918A publication Critical patent/JP2021523918A/ja
Publication of JPWO2019220390A5 publication Critical patent/JPWO2019220390A5/ja
Publication of JP2021523918A5 publication Critical patent/JP2021523918A5/ja
Priority to JP2023212606A priority Critical patent/JP2024037930A/ja
Application granted granted Critical
Publication of JP7407740B2 publication Critical patent/JP7407740B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564243A 2018-05-18 2019-05-16 Tlr7/tlr8阻害剤の結晶形態 Active JP7407740B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023212606A JP2024037930A (ja) 2018-05-18 2023-12-18 Tlr7/tlr8阻害剤の結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018087448 2018-05-18
CNPCT/CN2018/087448 2018-05-18
PCT/IB2019/054066 WO2019220390A1 (en) 2018-05-18 2019-05-16 Crystalline forms of a tlr7/tlr8 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023212606A Division JP2024037930A (ja) 2018-05-18 2023-12-18 Tlr7/tlr8阻害剤の結晶形態

Publications (4)

Publication Number Publication Date
JP2021523918A JP2021523918A (ja) 2021-09-09
JPWO2019220390A5 JPWO2019220390A5 (https=) 2022-05-20
JP2021523918A5 true JP2021523918A5 (https=) 2022-05-20
JP7407740B2 JP7407740B2 (ja) 2024-01-04

Family

ID=67145832

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564243A Active JP7407740B2 (ja) 2018-05-18 2019-05-16 Tlr7/tlr8阻害剤の結晶形態
JP2023212606A Pending JP2024037930A (ja) 2018-05-18 2023-12-18 Tlr7/tlr8阻害剤の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023212606A Pending JP2024037930A (ja) 2018-05-18 2023-12-18 Tlr7/tlr8阻害剤の結晶形態

Country Status (13)

Country Link
US (2) US12084460B2 (https=)
EP (1) EP3793998A1 (https=)
JP (2) JP7407740B2 (https=)
KR (1) KR20210013554A (https=)
CN (1) CN112119078A (https=)
AR (1) AR117573A1 (https=)
AU (1) AU2019268583B2 (https=)
BR (1) BR112020022738A2 (https=)
CA (1) CA3097312A1 (https=)
CL (1) CL2020002967A1 (https=)
MX (2) MX2020012259A (https=)
TW (2) TW202417000A (https=)
WO (1) WO2019220390A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ. ホフマン-ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
EP3802539B1 (en) 2018-06-05 2023-09-20 F. Hoffmann-La Roche AG Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
EP3807270B1 (en) 2018-06-12 2023-09-13 F. Hoffmann-La Roche AG Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
CN112584903B (zh) 2018-07-23 2025-12-23 豪夫迈·罗氏有限公司 用于自身免疫性疾病治疗的哌嗪化合物
EP3847169A1 (en) 2018-09-04 2021-07-14 F. Hoffmann-La Roche AG Benzothiazole compounds for the treatment of autoimmune diseases
EP3847173B1 (en) 2018-09-06 2023-04-12 F. Hoffmann-La Roche AG Novel pyrazolopyridine compounds for the treatment of autoimmune disease
US11548884B2 (en) 2018-09-06 2023-01-10 Hoffmann-La Roche Inc. Cyclic amidine compounds for the treatment of autoimmune disease
WO2021084022A1 (en) 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
WO2021099406A1 (en) 2019-11-20 2021-05-27 F. Hoffmann-La Roche Ag Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
US20240317735A1 (en) 2020-07-14 2024-09-26 Hoffmann-La Roche Inc. Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease
CR20230478A (es) 2021-04-16 2023-11-30 Gilead Sciences Inc Compuestos de tienopirrol.
KR20240056747A (ko) 2021-09-10 2024-04-30 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
PE20250401A1 (es) 2021-09-24 2025-02-11 Hoffmann La Roche Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias
AU2023207313A1 (en) * 2022-01-11 2024-06-13 Novartis Ag Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2222545A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
AU2006279548A1 (en) 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
DK2812331T3 (en) 2012-02-08 2019-04-08 Janssen Sciences Ireland Unlimited Co PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
EP3341375B1 (en) 2015-08-25 2022-04-13 BeiGene, Ltd. Process for preparing parp inhibitor, crystalline forms, and uses thereof
GB2566245B (en) * 2016-06-30 2020-09-30 Kimberly Clark Co Method of manufacturing a foam and fiber composite
HRP20220144T1 (hr) * 2016-09-09 2022-04-15 Novartis Ag Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora

Similar Documents

Publication Publication Date Title
JP2021523918A5 (https=)
AU2019283921B2 (en) Indole carboxamide compounds useful as kinase inhibitors
CN111315737B (zh) 经砜吡啶烷基酰胺取代的杂芳基化合物
JPWO2019220390A5 (https=)
TWI287545B (en) New pyridazin-3(2h)-one derivatives
JP4142621B2 (ja) 純結晶形態の5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニルおよび合成方法
TW200526593A (en) New pyridazin-3(2H)-one derivatives
JPWO2023099612A5 (https=)
EP3209652B1 (en) Tricyclic atropisomer compounds
JP2006503845A (ja) Cb2受容体モジュレーターとしてのピリジン誘導体
JP2009515836A5 (https=)
PT3013814T (pt) Compostos de tetrahidrocarbazol e carbazol carboxamida substituídos úteis como inibidores de quinases
CN116113416A (zh) 四环类衍生物、其制备方法和其医药上的用途
JP2020507624A5 (https=)
JP2005529084A (ja) 結晶性パレコキシブナトリウム
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
WO2024251080A1 (zh) 3,4-二氢酞嗪-1(2h)-酮类衍生物及其制备方法和用途
CN104994851A (zh) 作为crac通道抑制剂的基于吡唑基的甲酰胺i
JP2016516691A (ja) カリウムイオンチャネル阻害剤としてのイソキノリン
JP2005529084A5 (https=)
JP6473820B2 (ja) 塩酸ヨンケナフィルの多形体及びその調製方法、組成物並びに用途
JP2004530706A (ja) 純粋な結晶形態にある5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニル及び合成方法
CN104884058A (zh) 作为crac通道抑制剂的基于吡唑基的甲酰胺ii
EP3495350B1 (en) Compound inhibiting formation of c-myc/max/dna complex
KR20060127892A (ko) 온단세트론의 신규한 다형 형태, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 항구토제로서의 이의 용도